Protein Kinases II, London, UK
Event May 15
Protein Kinases II continues on from the first SCI Protein Kinases meeting held in May 2001 - the same week that Gleevec™, the first protein kinase inhibitor was launched. The interest in protein kinases as therapeutic targets in the pharmaceutical and agribusinesses continues unabated with the expectation that useful drugs and active ingredients can be identified and brought to market. This meeting is aimed at medicinal chemists interested in furthering their knowledge of kinase lead identification and optimisation, and anyone who wishes to gain a perspective on the progress being made in selective inhibition of diverse members of the protein kinases family.
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018